Physician profile
Robert C Layman
NPI 1699769836
$7,829.69
in general payments reported to CMS, 2019-2025
24 companies · $627 in 2025
The $627 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $182 · 2021: $1,181 · 2022: $1,140 · 2023: $2,265 · 2024: $1,274 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746 · Travel and Lodging: $1,246 · Entertainment: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,745.66 |
| Travel and Lodging | $1,246.35 |
| Entertainment | $173.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,462.27 | 2019-2025 | Dailies Aqua Comfort Plus, Air Optix, Dailies Total1 Multifocal |
| Coopervision INC. | $827.13 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Paragon Crt |
| Bausch & Lomb Americas INC. | $622.15 | 2022-2025 | Infuse, Miebo, Xiidra |
| Abbvie INC. | $424.63 | 2022-2024 | |
| Optos, INC. | $415.91 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $401.40 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $397.63 | 2019-2025 | Cequa |
| Allergan, INC. | $393.63 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $364.85 | 2019-2025 | Acuvue |
| Optovue, INC. | $324.93 | 2019-2021 | |
| Glaukos Corporation | $247.52 | 2024 | Radius |
| Biotissue Holdings INC. | $188.13 | 2019-2024 | |
| Dompe US, INC. | $173.65 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $125.31 | 2022-2025 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $124.37 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $111.92 | 2020-2023 | Opd-III |
| Tarsus Pharmaceuticals, INC. | $50.28 | 2024-2025 | Xdemvy |
| Heru, INC. | $38.89 | 2022 | |
| Visioneering Technologies, INC. | $34.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.48 | 2019-2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Lkc Technologies, INC. | $17.61 | 2025 | |
| Eyevance Pharmaceuticals LLC | $16.97 | 2022 | |
| Integra Lifesciences Corporation | $15.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Layman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.